Moore Capital Management LP Buys Shares of 47,119 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Moore Capital Management LP purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 47,119 shares of the medical equipment provider's stock, valued at approximately $4,977,000.

Other institutional investors have also added to or reduced their stakes in the company. Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth approximately $25,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet in the 4th quarter worth $36,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $39,000. OFI Invest Asset Management bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $40,000. Finally, Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 86.6% in the fourth quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 206 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZBH. Truist Financial set a $101.00 price objective on Zimmer Biomet in a report on Tuesday, May 6th. Robert W. Baird decreased their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Royal Bank of Canada lowered their price objective on Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Raymond James reduced their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and an average price target of $113.45.

Zimmer Biomet Price Performance

ZBH stock traded up $0.05 during mid-day trading on Friday, hitting $96.78. The company had a trading volume of 2,339,193 shares, compared to its average volume of 1,752,324. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $19.15 billion, a price-to-earnings ratio of 21.75, a P/E/G ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.92 and a 12-month high of $121.30. The company has a 50-day moving average price of $103.62 and a 200 day moving average price of $105.92.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.94 earnings per share. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.99%. Zimmer Biomet's dividend payout ratio is presently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.